Patents by Inventor Harley R. McDaniel

Harley R. McDaniel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5786342
    Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 28, 1998
    Assignee: Carrington Laboratories, Inc.
    Inventors: Robert H. Carpenter, Harley R. McDaniel, Bill H. McAnalley
  • Patent number: 5780453
    Abstract: Method for reducing symptoms associated with multiple sclerosis in an animal by administering to the animal an effective amount of an acetylated polymeric mannan derivative.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 14, 1998
    Assignee: Carrington Laboratories, Inc.
    Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
  • Patent number: 5773425
    Abstract: Methods for the treatment of sarcoma, carcinoma and lymphoma in an animal by administering to the animal an effective amount of a polymeric acetylated mannan derivative.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 30, 1998
    Assignee: Carrington Laboratories, Inc.
    Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
  • Patent number: 5703060
    Abstract: Methods of prevention and treatment of infections and infestations in an animal by administering to the animal an effective amount of an acetylated mannan derivative.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 30, 1997
    Assignee: Carrington Laboratories Inc.
    Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
  • Patent number: 5587364
    Abstract: Methods of treating inflammatory diseases in an animal by administering to the animal an effective amount of a polymeric acetylated mannan derivative of aloe origin.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 24, 1996
    Assignee: Carrington Laboratories, Inc.
    Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
  • Patent number: 5468737
    Abstract: A method for promoting wound healing involving initiating and accelerating wound repair and tissue regeneration in an animal by systemic administration of a bioactive polysaccharide derived from aloe vera plant.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: November 21, 1995
    Assignee: Carrington Laboratories, Inc.
    Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
  • Patent number: 5441943
    Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: August 15, 1995
    Assignee: Carrington Laboratories, Inc.
    Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
  • Patent number: 5308838
    Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.
    Type: Grant
    Filed: April 7, 1992
    Date of Patent: May 3, 1994
    Assignee: Carrington Laboratories, Inc.
    Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel
  • Patent number: 5118673
    Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.
    Type: Grant
    Filed: July 27, 1990
    Date of Patent: June 2, 1992
    Assignee: Carrington Laboratories, Inc.
    Inventors: Robert H. Carpenter, Harley R. McDaniel, Bill H. McAnalley
  • Patent number: 5106616
    Abstract: Acemannan has now been discovered to be a potent inducer of Interleukin 1 (Il-1) and prostaglandin E.sub.2 (PGE.sub.2) production by human peripheral blood adherent cells in culture. Il-1 has been shown to be an important macrophage product and is associated with influencing the activity and production of T lymphocytes, fibroblasts, B lymphocytes and endothelial cells. Acemannan has no demonstrated toxicity, and acts as an adjuvant and immunoenhancer. Administration of an amount of acemannan sufficient to stimulate monocytes and macrophages not only produces Il-1 and PGE.sub.2 but also stimulates phagocytosis, increases antibody production, enhances antiviral activity in the serum and, in those patients with AIDS/ARC, produces defective HIV virus.Acemannan has been shown to affect the rate of virus production in viral vaccine master seed cultures by accelerating the rate of viral replication. In addition, acemannan is a potent adjuvant to viral vaccines in chickens.
    Type: Grant
    Filed: August 5, 1988
    Date of Patent: April 21, 1992
    Assignee: Carrington Laboratories, Inc.
    Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel